Market Closed -
Nasdaq
03:59:44 2024-06-04 pm EDT
|
5-day change
|
1st Jan Change
|
4
USD
|
+0.50%
|
|
-3.85%
|
-29.20%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
949.7
|
368.3
|
282.8
|
243.3
|
-
|
-
|
Enterprise Value (EV)
1 |
603.6
|
105.5
|
50.43
|
121.8
|
71.96
|
-61.11
|
P/E ratio
|
-6.9
x
|
-3.31
x
|
-2.15
x
|
-1.89
x
|
-2.02
x
|
-2.03
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
35.8
x
|
37.8
x
|
13.7
x
|
EV / Revenue
|
-
|
-
|
-
|
17.9
x
|
11.2
x
|
-3.45
x
|
EV / EBITDA
|
-8.53
x
|
-0.97
x
|
-0.37
x
|
-0.85
x
|
-0.4
x
|
0.32
x
|
EV / FCF
|
-8.74
x
|
-1
x
|
-0.8
x
|
-0.99
x
|
-0.51
x
|
0.38
x
|
FCF Yield
|
-11.4%
|
-99.9%
|
-125%
|
-101%
|
-196%
|
260%
|
Price to Book
|
2.75
x
|
1.32
x
|
1.58
x
|
4.05
x
|
3.92
x
|
2.2
x
|
Nbr of stocks (in thousands)
|
46,506
|
48,399
|
50,062
|
61,140
|
-
|
-
|
Reference price
2 |
20.42
|
7.610
|
5.650
|
4.000
|
4.000
|
4.000
|
Announcement Date
|
3/29/22
|
3/16/23
|
3/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
6.803
|
6.429
|
17.73
|
EBITDA
1 |
-
|
-70.75
|
-108.6
|
-137.1
|
-142.8
|
-178.8
|
-190
|
EBIT
1 |
-
|
-72.88
|
-112.4
|
-143.3
|
-146.9
|
-165.5
|
-189.6
|
Operating Margin
|
-
|
-
|
-
|
-
|
-2,159.81%
|
-2,573.57%
|
-1,069.06%
|
Earnings before Tax (EBT)
1 |
-
|
-73.96
|
-108.5
|
-135
|
-138.5
|
-160.3
|
-184.8
|
Net income
1 |
-35.88
|
-73.96
|
-108.5
|
-135.4
|
-138.7
|
-160.4
|
-184.7
|
Net margin
|
-
|
-
|
-
|
-
|
-2,039.56%
|
-2,494.35%
|
-1,041.72%
|
EPS
2 |
-6.700
|
-2.960
|
-2.300
|
-2.630
|
-2.120
|
-1.979
|
-1.975
|
Free Cash Flow
1 |
-
|
-69.1
|
-105.4
|
-62.84
|
-123.6
|
-141
|
-159
|
FCF margin
|
-
|
-
|
-
|
-
|
-1,816.47%
|
-2,193.07%
|
-896.82%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
6/4/21
|
3/29/22
|
3/16/23
|
3/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
1.064
|
1.349
|
1.349
|
1.777
|
1.8
|
1.8
|
EBITDA
|
-
|
-
|
-
|
-
|
-31.42
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-23.39
|
-24.3
|
-27.23
|
-28.36
|
-32.49
|
-34.26
|
-37.22
|
-36.97
|
-34.86
|
-36.01
|
-36.25
|
-38.02
|
-37.59
|
-44.16
|
-46.26
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-3,384.49%
|
-2,687.41%
|
-2,818.53%
|
-2,114.94%
|
-2,453.43%
|
-2,569.96%
|
Earnings before Tax (EBT)
1 |
-23.4
|
-23.93
|
-26.47
|
-27.32
|
-30.78
|
-32.04
|
-34.99
|
-34.71
|
-33.27
|
-31.88
|
-34.3
|
-36.22
|
-36.21
|
-43.23
|
-45.41
|
Net income
1 |
-23.4
|
-23.93
|
-26.47
|
-27.32
|
-30.78
|
-32.04
|
-35.18
|
-34.88
|
-33.25
|
-31.97
|
-34.3
|
-36.22
|
-36.21
|
-43.23
|
-45.41
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-3,004.51%
|
-2,543.24%
|
-2,685.48%
|
-2,037.24%
|
-2,401.4%
|
-2,522.96%
|
EPS
2 |
-0.1100
|
-0.5100
|
-0.5700
|
-0.5800
|
-0.6300
|
-0.6500
|
-0.7100
|
-0.7000
|
-0.5800
|
-0.5300
|
-0.5461
|
-0.5522
|
-0.5184
|
-0.5433
|
-0.5100
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/29/22
|
5/11/22
|
8/11/22
|
11/10/22
|
3/16/23
|
5/11/23
|
8/10/23
|
11/9/23
|
3/14/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
346
|
263
|
232
|
122
|
171
|
304
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-69.1
|
-105
|
-62.8
|
-124
|
-141
|
-159
|
ROE (net income / shareholders' equity)
|
-
|
-49.5%
|
-35.1%
|
-60.1%
|
-60.9%
|
-135%
|
-75.5%
|
ROA (Net income/ Total Assets)
|
-
|
-35.6%
|
-30.6%
|
-41.9%
|
-42%
|
-33.6%
|
-29.1%
|
Assets
1 |
-
|
207.9
|
354.4
|
323.1
|
330.5
|
477.2
|
634.2
|
Book Value Per Share
2 |
-
|
7.430
|
5.750
|
3.570
|
0.9900
|
1.020
|
1.820
|
Cash Flow per Share
|
-
|
-
|
-1.960
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
9.73
|
12.9
|
19
|
12
|
8.97
|
9.37
|
Capex / Sales
|
-
|
-
|
-
|
-
|
176.4%
|
139.58%
|
52.86%
|
Announcement Date
|
6/4/21
|
3/29/22
|
3/16/23
|
3/14/24
|
-
|
-
|
-
|
Average target price
15
USD Spread / Average Target +275.00% Consensus |
1st Jan change
|
Capi.
|
---|
| -29.20% | 243M | | +46.19% | 56.65B | | -6.14% | 39.44B | | +39.19% | 39.03B | | -6.65% | 26.86B | | +12.33% | 26.75B | | -21.78% | 19.03B | | -0.35% | 12.28B | | +24.18% | 12.26B | | +28.38% | 12.04B |
Other Biotechnology & Medical Research
|